Preclinical News and Research

RSS
Inhibitex reports net loss of $4.8M for first-quarter 2010

Inhibitex reports net loss of $4.8M for first-quarter 2010

GRNCM1 do not cause cardiac arrhythmias after transplantation: Preclinical study

GRNCM1 do not cause cardiac arrhythmias after transplantation: Preclinical study

Sinovac Biotech's sales for first-quarter 2010 decrease 32% to $4.4M

Sinovac Biotech's sales for first-quarter 2010 decrease 32% to $4.4M

Chimerix commences first-in-human study of CMX157 for HIV

Chimerix commences first-in-human study of CMX157 for HIV

Repligen files IND for Phase 1 study of RG2833 selective HDAC-3 inhibitor for Friedreich's ataxia

Repligen files IND for Phase 1 study of RG2833 selective HDAC-3 inhibitor for Friedreich's ataxia

Researchers provide better understanding of anti-cell death proteins and potential antagonist to defeat them

Researchers provide better understanding of anti-cell death proteins and potential antagonist to defeat them

Aeterna Zentaris posts net loss of $5.9 million for first-quarter 2010

Aeterna Zentaris posts net loss of $5.9 million for first-quarter 2010

ACHN reports net loss of $5.6M for first-quarter 2010: MicroStockProfit.com

ACHN reports net loss of $5.6M for first-quarter 2010: MicroStockProfit.com

pSivida reports consolidated net loss of $2.7 million for third-quarter 2010

pSivida reports consolidated net loss of $2.7 million for third-quarter 2010

NovaBay first-quarter net loss increases to $1.6 million

NovaBay first-quarter net loss increases to $1.6 million

Pro-Pharmaceuticals reports net loss applicable to common stock of $2.8M for first-quarter 2010

Pro-Pharmaceuticals reports net loss applicable to common stock of $2.8M for first-quarter 2010

Key mechanisms for delivery of LNP-encapsulated siRNAs to the liver

Key mechanisms for delivery of LNP-encapsulated siRNAs to the liver

Evotec first-quarter operating loss decreases 93% to € 1.5 m

Evotec first-quarter operating loss decreases 93% to € 1.5 m

COTI announces favourable independent pre-IND gap analysis report for novel oncology drug candidate

COTI announces favourable independent pre-IND gap analysis report for novel oncology drug candidate

NiKem Research receives Italian authorization to perform toxicology studies of NCEs in rodents

NiKem Research receives Italian authorization to perform toxicology studies of NCEs in rodents

Optivia Biotechnology launches OptiDDI Suite for assessing transporter-related DDIs

Optivia Biotechnology launches OptiDDI Suite for assessing transporter-related DDIs

Researchers develop anti-angiogenic molecule SR16388 for treatment of MM

Researchers develop anti-angiogenic molecule SR16388 for treatment of MM

Vetter signs preferred partnership agreement with Sentry BioPharma Services

Vetter signs preferred partnership agreement with Sentry BioPharma Services

CEA-Leti launches TARGET-PDT project to increase effectiveness of PDT for treating cancer

CEA-Leti launches TARGET-PDT project to increase effectiveness of PDT for treating cancer

CEVEC, Aragen Bioscience announce strategic license agreement

CEVEC, Aragen Bioscience announce strategic license agreement

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.